Tonix Q2 revenue rises sharply on TONMYA launch

Tonix Pharmaceuticals Holding

10/08/2026 12:11

Overview
US biopharma firm's Q2 net product revenue rose sharply year-over-year, driven by TONMYA launch
TONMYA net sales nearly tripled quarter-over-quarter as coverage and prescriptions expanded
Company's net loss widened on higher R&D and selling expenses for pipeline and commercial activities

Outlook
Company expects to deploy 50 new TONMYA sales representatives by September 2026
Tonix expects Phase 2 study of TNX-4800 for Lyme disease to start in Q1 2027
Company believes cash resources will fund operations into early Q2 2027

Result Drivers
TONMYA LAUNCH - Net sales of TONMYA nearly tripled quarter-over-quarter, driven by expanded coverage and increased prescriptions
PRESCRIPTION GROWTH - Total prescriptions for TONMYA doubled and refills rose 207% quarter-over-quarter, reflecting broader patient access
SALES FORCE EXPANSION - Company is expanding its sales force to support further TONMYA uptake, with 50 new representatives expected to deploy by September

Company press release: ID:nGNXbdLmxf

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
 
$40.55 mln
 
Q2 Operating Income
 
-$42.54 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Tonix Pharmaceuticals Holding Corp. is $34.00, about 182.6% above its August 7 closing price of $12.03

Reuters Recommended Reads
Aug 7 - ANI Pharmaceuticals Q2 adjusted EPS beats on increased volume in specialty areas
Aug 7 - Soligenix Q2 net loss narrows as R&D expenses fall
Aug 7 - Gyre Therapeutics Q2 revenue beats estimates on higher ETUARY sales volumes

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)